Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O2ZI
|
|||
| Former ID |
DIB004646
|
|||
| Drug Name |
90Y-labeled humanized anti-Tac mab
|
|||
| Synonyms |
90Y-HAT; 90Y-labeled humanized anti-Tac monoclonal antobody, National Cancer Institute
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C85.9] | Phase 1/2 | [1], [2] | |
| Company |
National Cancer Institute
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00001575) Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia. U.S. National Institutes of Health. | |||
| REF 2 | Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene. 2007 May 28;26(25):3699-703. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.